| [1] | Li B., Manan R.S., Liang S.Q., et al. (2023). Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat. Biotechnol. 41:1410−1415. DOI:10.1038/s41587-023-01679-x |
| [2] | Dhungel B.P., Xu H., Nagarajah R., et al. (2025). An alternate receptor for adeno-associated viruses. Cell 188:4924−4935. DOI:10.1016/j.cell.2025.06.026 |
| [3] | Blanco E., Shen H. and Ferrari M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33:941−951. DOI:10.1038/nbt.3330 |
| [4] | Wang Q., Chen Z., Zhang G., et al. (2026). Commensal-driven serotonin production modulates in vivo delivery of synthetic and viral vectors. Science 391:eadu7686. DOI:10.1126/science.adu7686 |
| [5] | He Y., Brouwers B., Liu H., et al. (2022). Human loss-of-function variants in the serotonin 2C receptor associated with obesity and maladaptive behavior. Nat. Med. 28:2537−2546. DOI:10.1038/s41591-022-02106-5 |
| Yang X., Chen P., Gao Y.-Z., et al. (2026). Beyond carrier design: The gut microbiota–serotonin axis modulates systemic delivery in mouse models. The Innovation Life 4:100238. https://doi.org/10.59717/j.xinn-life.2026.100238 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
The gut microbiota–serotonin axis regulates systemic in vivo delivery